Tags

Type your tag names separated by a space and hit enter

Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
J Clin Endocrinol Metab. 2012 May; 97(5):E755-9.JC

Abstract

INTRODUCTION

B cells are known to play a key role in the pathogenesis of autoimmune disease. B lymphocyte activating factor (BAFF), a member of TNF family, promotes autoantibody production by increasing B cell survival and proliferation. Serum BAFF concentrations have been found to be increased in systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's syndrome.

OBJECTIVE

We have measured serum BAFF concentrations in patients with Graves' disease (GD) with or without Graves' orbitopathy (GO) and in active GO in relation to immunosuppressive treatment.

METHODS

Forty-two patients and nine normal controls were studied. Thirty-four patients had GO, which was active in 23. Of these, nine were treated with rituximab (RTX) and 14 with i.v. methylprednisolone (MP). Serum BAFF concentrations were measured at baseline in all patients, at peripheral B cell depletion and repopulation after RTX, and after therapy with MP.

RESULTS

Serum basal BAFF concentrations in GD patients were significantly higher when compared with normal controls (P = 0.0001), and no difference was observed in those with active or inactive GO. Serum BAFF concentrations were also significantly correlated with serum antithyroglobulin antibodies (P = 0.04) but not with sex, age, smoking habits, therapy for thyroid disease, and serum antithyroperoxidase antibodies and TSH receptor antibodies. After RTX, there was an increase of serum BAFF concentrations at the time of B cell depletion (P = 0.02) but also at B cell repopulation (P = 0.04). In patients treated with MP, serum BAFF concentrations decreased significantly after therapy (P < 0.01).

CONCLUSIONS

We report that serum BAFF concentrations are elevated in patients with GD, in whom hyperthyroidism is known to be based on a B-cell-driven pathophysiological mechanism. In active GO, BAFF further increases after therapy with RTX as a consequence of the B cell depletion per se. The decrease of serum BAFF after iv steroids suggests that MP may exert an immunosuppressive effect by modifying B-cell-derived immune reactions.

Authors+Show Affiliations

Endocrine Unit, Department of Medical Sciences, University of Milan and Fondazione Cà Granda Istituto di Ricovero e Cura a Carattere Scientifico, 20122 Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22399512

Citation

Vannucchi, Guia, et al. "Serum BAFF Concentrations in Patients With Graves' Disease and Orbitopathy Before and After Immunosuppressive Therapy." The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 5, 2012, pp. E755-9.
Vannucchi G, Covelli D, Currò N, et al. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy. J Clin Endocrinol Metab. 2012;97(5):E755-9.
Vannucchi, G., Covelli, D., Currò, N., Dazzi, D., Maffini, A., Campi, I., Bonara, P., Guastella, C., Pignataro, L., Ratiglia, R., Beck-Peccoz, P., & Salvi, M. (2012). Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy. The Journal of Clinical Endocrinology and Metabolism, 97(5), E755-9. https://doi.org/10.1210/jc.2011-2614
Vannucchi G, et al. Serum BAFF Concentrations in Patients With Graves' Disease and Orbitopathy Before and After Immunosuppressive Therapy. J Clin Endocrinol Metab. 2012;97(5):E755-9. PubMed PMID: 22399512.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy. AU - Vannucchi,Guia, AU - Covelli,Danila, AU - Currò,Nicola, AU - Dazzi,Davide, AU - Maffini,Antonia, AU - Campi,Irene, AU - Bonara,Paola, AU - Guastella,Claudio, AU - Pignataro,Lorenzo, AU - Ratiglia,Roberto, AU - Beck-Peccoz,Paolo, AU - Salvi,Mario, Y1 - 2012/03/07/ PY - 2012/3/9/entrez PY - 2012/3/9/pubmed PY - 2012/7/24/medline SP - E755 EP - 9 JF - The Journal of clinical endocrinology and metabolism JO - J. Clin. Endocrinol. Metab. VL - 97 IS - 5 N2 - INTRODUCTION: B cells are known to play a key role in the pathogenesis of autoimmune disease. B lymphocyte activating factor (BAFF), a member of TNF family, promotes autoantibody production by increasing B cell survival and proliferation. Serum BAFF concentrations have been found to be increased in systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's syndrome. OBJECTIVE: We have measured serum BAFF concentrations in patients with Graves' disease (GD) with or without Graves' orbitopathy (GO) and in active GO in relation to immunosuppressive treatment. METHODS: Forty-two patients and nine normal controls were studied. Thirty-four patients had GO, which was active in 23. Of these, nine were treated with rituximab (RTX) and 14 with i.v. methylprednisolone (MP). Serum BAFF concentrations were measured at baseline in all patients, at peripheral B cell depletion and repopulation after RTX, and after therapy with MP. RESULTS: Serum basal BAFF concentrations in GD patients were significantly higher when compared with normal controls (P = 0.0001), and no difference was observed in those with active or inactive GO. Serum BAFF concentrations were also significantly correlated with serum antithyroglobulin antibodies (P = 0.04) but not with sex, age, smoking habits, therapy for thyroid disease, and serum antithyroperoxidase antibodies and TSH receptor antibodies. After RTX, there was an increase of serum BAFF concentrations at the time of B cell depletion (P = 0.02) but also at B cell repopulation (P = 0.04). In patients treated with MP, serum BAFF concentrations decreased significantly after therapy (P < 0.01). CONCLUSIONS: We report that serum BAFF concentrations are elevated in patients with GD, in whom hyperthyroidism is known to be based on a B-cell-driven pathophysiological mechanism. In active GO, BAFF further increases after therapy with RTX as a consequence of the B cell depletion per se. The decrease of serum BAFF after iv steroids suggests that MP may exert an immunosuppressive effect by modifying B-cell-derived immune reactions. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/22399512/Serum_BAFF_concentrations_in_patients_with_Graves'_disease_and_orbitopathy_before_and_after_immunosuppressive_therapy_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2011-2614 DB - PRIME DP - Unbound Medicine ER -